|1.||Stewart, William C: 26 articles (01/2013 - 06/2002)|
|2.||Stewart, W C: 18 articles (10/2010 - 06/2000)|
|3.||Konstas, Anastasios G P: 15 articles (06/2014 - 06/2002)|
|4.||Stewart, Jeanette A: 10 articles (01/2013 - 03/2003)|
|5.||Rossetti, Luca: 9 articles (04/2015 - 08/2002)|
|6.||Hollander, David A: 9 articles (01/2014 - 05/2008)|
|7.||Inoue, Kenji: 8 articles (01/2014 - 08/2006)|
|8.||Tomita, Goji: 7 articles (01/2014 - 08/2006)|
|9.||Alm, Albert: 7 articles (01/2014 - 08/2002)|
|10.||Baudouin, Christophe: 7 articles (02/2013 - 05/2004)|
07/01/2011 - "The introduction of the first prostaglandin analogue, latanoprost, dramatically improved treatment persistence for glaucoma patients. "
04/01/2000 - "These results suggest that latanoprost may be very effective in some patients with poorly controlled glaucoma on multiple therapy."
11/01/2002 - "The criterion for success was defined as having an IOP reduction of at least 20% from baseline or a final IOP of less than 22 mm Hg. Several clinical pretreatment variables (age, gender, ocular laterality, type of glaucoma, number of antiglaucomatous medications at study entry, pretreatment IOP) were analyzed for a significant effect on the efficacy of latanoprost additive therapy. "
02/01/2001 - "These effects of latanoprost may be beneficial in the management of glaucoma patients."
03/01/2003 - "However, latanoprost was effective in only a minority of pediatric cases of glaucoma and is contraindicated in all forms of uveitic glaucoma. "
|2.||Ocular Hypertension (Glaucoma, Suspect)
07/01/2014 - "PF latanoprost was efficacious in reducing IOP in a randomized, investigator-masked, multinational trial in patients with POAG/ocular hypertension (n = 404). "
01/01/2007 - "The study suggests that patients with ocular hypertension already treated with latanoprost monotherapy will continue to have, on average, at least midterm stable pressures, low incidence of side effects and discontinuations, as well as "very good" to "excellent" physician ratings of efficacy, tolerability, and patient satisfaction."
01/01/2007 - "353 patients with ocular hypertension were included and treated with latanoprost monotherapy historically (1.4 +/- 1.3 years) and within the observational period of the study for a mean of 2.2 +/- 1.1 years. "
01/01/2007 - "A subanalysis of patients with ocular hypertension who were previously treated on latanoprost monotherapy and continued within the study on this same medication for at least 6 months. "
09/01/1993 - "In a randomized, double-masked, placebo-controlled study, PhXA41 (0.006%) was given topically twice daily for 1 week to one eye each of 22 volunteers with normotension or ocular hypertension. "
|3.||Open-Angle Glaucoma (Glaucoma, Open Angle)
11/01/2002 - "To assess the efficacy of latanoprost as additive therapy in patients with open-angle glaucoma and an intraocular pressure (IOP) deemed to be too high on maximum tolerated medical therapy. "
12/01/2003 - "Latanoprost monotherapy is a safe and effective alternative for many patients with open angle glaucoma requiring dual topical ocular hypotensive therapy for IOP control."
03/01/2008 - "First-line therapy with latanoprost 0.005% results in improved ocular circulation in newly diagnosed primary open-angle glaucoma patients: a prospective, 6-month, open-label study."
06/16/2015 - "In open-angle glaucoma, latanoprost improved visual field preservation."
05/01/2002 - "[Efficacy of latanoprost monotherapy treatment in primary open-angle glaucoma]."
|4.||Angle-Closure Glaucoma (Glaucoma, Angle Closure)
01/01/2009 - "latanoprost, a prostaglandin analogue, is effective in reducing IOP in chronic angle closure glaucoma patients and its efficacy is not affected by the degree of angle closure by peripheral anterior synechiae."
02/01/2005 - "The aim of this study was to evaluate the efficacy of 0.005% latanoprost in lowering intraocular pressure (IOP) in patients with chronic angle-closure glaucoma (CACG) and no visible ciliary-body face. "
02/01/2005 - "Efficacy of latanoprost in patients with chronic angle-closure glaucoma and no visible ciliary-body face: a preliminary study."
08/01/2002 - "Two independent, prospective trials were recently conducted to assess the efficacy of latanoprost in reducing intraocular pressure (IOP) in patients with primary angle-closure glaucoma (PACG). "
01/01/2009 - "Efficacy of latanoprost in management of chronic angle closure glaucoma."
|5.||Low Tension Glaucoma
03/01/2003 - "NTG: Latanoprost is effective in normal tension glaucoma (NTG), lowering IOP, improving pulsatile ocular blood flow and increasing ocular perfusion pressure. "
12/01/2005 - "To evaluate the intraocular pressure (IOP)-lowering efficacy of latanoprost in normal-tension glaucoma (NTG). "
09/01/2003 - "To study the effect of instillation of latanoprost on the diurnal variation in the intraocular pressure(IOP), blood pressure, and pulse rate in patients with normal-tension glaucoma(NTG). "
02/01/1997 - "Reduced intraocular pressure and increased ocular perfusion pressure in normal tension glaucoma: a review of short-term studies with three dose regimens of latanoprost treatment."
04/01/2015 - "To evaluate the long-term effect of latanoprost on central corneal thickness (CCT) in patients with normal-tension glaucoma (NTG). "
|2.||Intraocular Lenses (Intraocular Lens)